Peptide Research Library

Semaglutide

Main evidence: Human clinical trials. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

Evidence-focused, review-only summary for informed discussion; not a prescription, personal dosing guide, or individualized medical advice. Australian brand labels, trial populations, and dated claims below are kept distinct.

What the sources say

• The product information lists gastrointestinal effects such as nausea, vomiting, diarrhoea, and constipation, and warns about pancreatitis, gallbladder disease, dehydration-related kidney problems, and hypoglycaemia risk when used with insulin or sulfonylureas. This is a concise safety summary, not a complete label. (Manufacturer information; TGA Australian Product Information: Wegovy (semaglutide) solution for injection, 2024-09-04)
• The TGA says some epidemiological studies indicate an increased risk of non-arteritic anterior ischaemic optic neuropathy (NAION) during semaglutide treatment. Sudden or partial vision loss warrants urgent ophthalmological assessment; the update describes a safety signal and warning, not an individualized risk estimate. (Educator material (not peer reviewed); TGA Medicine Safety Update: GLP-1 RAs and rare vision disorder (NAION), 2026-07-23)
• The TGA states that GLP-1 medicines are not recommended during pregnancy and advises effective contraception during treatment. This is general regulatory information, not individualized reproductive advice. (Educator material (not peer reviewed); TGA Medicine Safety Update: Updated contraception advice for Mounjaro (tirzepatide) and pregnancy reminder, 2025-12-01)
• The TGA aligned product warnings to monitor for new or worsening depression, suicidal thoughts or behaviours, or unusual mood changes. Its expert committee found the available evidence insufficient to support a causal association; the warning should not be read as proof that semaglutide causes these outcomes. (Educator material (not peer reviewed); TGA Medicine Safety Update: GLP-1 RAs — warnings aligned over potential risk of suicidal thoughts or behaviours, 2025-12-01)
• The TGA warns that delayed gastric emptying can leave stomach contents despite routine fasting and may increase aspiration risk during general anaesthesia or deep sedation. Patients are advised to tell relevant clinicians, including anaesthetists, before a procedure. (Educator material (not peer reviewed); TGA Medicines Safety Update: Medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists — anaesthesia/deep sedation warning, 2025-06-03)
• The TGA registered Wegovy for provisional treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis (stages F2–F3). Continued approval depends on confirmatory evidence of clinical benefit. (Educator material (not peer reviewed); TGA registration record: Wegovy — provisional MASH indication (decision date), 2026-03-13)
• The TGA registered an Ozempic indication, alongside standard care, to reduce sustained kidney-function decline and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. (Educator material (not peer reviewed); TGA registration record: Ozempic — chronic kidney disease indication (decision date), 2025-08-15)
• The TGA distinguishes the Australian brands by approved use: Ozempic is marketed for type 2 diabetes, while Wegovy is marketed for chronic weight management. A semaglutide result or dose should not be transferred from one brand indication to another without checking the current Australian product information. (Educator material (not peer reviewed); TGA Medicines Safety Update: Medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists — anaesthesia/deep sedation warning, 2025-06-03)
• The TGA registered a separate Wegovy indication to reduce major adverse cardiovascular events in adults with established cardiovascular disease, BMI at least 27, and no established type 1 or type 2 diabetes. (Educator material (not peer reviewed); TGA registration record: Wegovy — major adverse cardiovascular event risk-reduction indication (decision date), 2024-12-16)
• The TGA registration record lists Wegovy as an Australian registered medicine for chronic weight management in adults: BMI at least 30, or BMI at least 27 and below 30 with a weight-related comorbidity, alongside reduced-energy diet and increased activity. (Educator material (not peer reviewed); TGA registration record: Wegovy — initial chronic weight-management indication (decision date), 2022-03-25)

Sources

1. TGA Australian Product Information: Wegovy (semaglutide) solution for injection (2024-09-04)
2. TGA Medicine Safety Update: GLP-1 RAs and rare vision disorder (NAION) (2026-07-23)
3. TGA Medicine Safety Update: Updated contraception advice for Mounjaro (tirzepatide) and pregnancy reminder (2025-12-01)
4. TGA Medicine Safety Update: GLP-1 RAs — warnings aligned over potential risk of suicidal thoughts or behaviours (2025-12-01)
5. TGA Medicines Safety Update: Medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists — anaesthesia/deep sedation warning (2025-06-03)
6. TGA registration record: Wegovy — provisional MASH indication (decision date) (2026-03-13)
7. TGA registration record: Ozempic — chronic kidney disease indication (decision date) (2025-08-15)
8. TGA registration record: Wegovy — major adverse cardiovascular event risk-reduction indication (decision date) (2024-12-16)
9. TGA registration record: Wegovy — initial chronic weight-management indication (decision date) (2022-03-25)

Dosing, stacking and protocol details are not published here.